Glenmark, APC Therapeutics Inks Deal To Expand Oncology Portfolio

Glenmark Pharmaceuticals has entered into a licensing agreement with U.S.-based APC Therapeutics Inc. for exclusive rights to a small molecule, oncology compound based on Antigen Presenting Cell (APC) biology, Glenmark informed the bourses on Wednesday.

The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

Under the terms of the agreement, Glenmark will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialisation worldwide.

Glenmark Pharmaceuticals was trading up by 0.2% at Rs 630 per share at 0917 hours IST on BSE. It hit a high of Rs 632.80 and a low of Rs 629.10 in the morning session.

Glenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

For Quick Trial – 8962000225 ✔ 
or mail us here:
or visit
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.